These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31236416)

  • 41. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
    Karpov IuA; Shubina AT
    Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
    [No Abstract]   [Full Text] [Related]  

  • 43. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
    Lombard L; Distiller L; Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
    [No Abstract]   [Full Text] [Related]  

  • 44. Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles.
    Feldman RD; Fitchett D; Hegele RA; Poulter NR
    Can J Cardiol; 2018 May; 34(5):532-535. PubMed ID: 29731015
    [No Abstract]   [Full Text] [Related]  

  • 45. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
    Hermann LS; Ranstam J; Vaaler S; Melander A
    Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
    Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
    J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
    [No Abstract]   [Full Text] [Related]  

  • 51. Insulin resistance: Impact on therapeutic developments in diabetes.
    Bailey CJ
    Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Stolar MW; Chilton RJ
    Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus.
    Hodge AM; Dowse GK; Zimmet PZ
    Diabet Med; 1996 May; 13(5):441-9. PubMed ID: 8737026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
    Krantz MJ
    Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
    [No Abstract]   [Full Text] [Related]  

  • 55. Implementation of a successful lifestyle intervention programme for New Zealand Maori to reduce the risk of type 2 diabetes and cardiovascular disease.
    McAuley KA; Murphy E; McLay RT; Chisholm A; Story G; Mann JI; Thomson R; Bell D; Williams SM; Goulding A; Wilson N
    Asia Pac J Clin Nutr; 2003; 12(4):423-6. PubMed ID: 14672866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular diseases and diabetes mellitus.
    Bandyopadhyay P
    Drug News Perspect; 2006; 19(6):369-75. PubMed ID: 16971974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on systemic management of diabetes.
    Masharani U; Rushakoff RJ
    Int Ophthalmol Clin; 2009; 49(2):13-33. PubMed ID: 19349784
    [No Abstract]   [Full Text] [Related]  

  • 58. [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].
    ; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes HP; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Sousa Uva M; Taskinen MR; Tendera M; Tuomilehto J; Valensi P; Zamorano JL;
    Kardiol Pol; 2013; 71 Suppl 11():S319-94. PubMed ID: 24297732
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F; Cosmi D
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
    Wikström G; Malmberg K; Rydén L
    Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.